Sio Gene Therapies

Sio Gene Therapies is a biotechnology company headquartered in New York, New York. Currently, the company employs 29 individuals. Sio Gene Therapies focuses on developing genetic medicines, particularly gene therapies, aimed at treating rare and prevalent diseases. Their clinical-stage pipeline includes potential cures for GM1 gangliosidosis and Tay-Sachs/Sandhoff diseases, both fatal pediatric conditions caused by single gene deficiencies. Additionally, they are researching gene therapies for Parkinson's disease, a condition affecting millions worldwide. Sio Gene Therapies distinguishes itself through its commitment to developing potentially curative AAV-based gene therapies. Their team comprises experienced gene therapy experts, and they collaborate with leading academic, industry, and patient advocacy organizations to accelerate their candidates through clinical trials. For further details, please visit Sio Gene Therapies' website at www.siogtx.com.